FDAnews Device Daily Bulletin

SORIN GROUP INITIATES CLEAR STUDY IN EUROPE

Dec. 7, 2005
A A

Sorin Group Cardiac Rhythm Management (CRM) Business Unit, an innovative leader in the hemodynamic management of heart failure, announced today that the first patient has been enrolled in the CLEAR (Clinical Evaluation of Advanced Resynchronization) multicenter clinical study. Patients included in the CLEAR study have advanced heart failure. Heart failure is a progressive condition in which the heart muscle weakens and gradually loses its ability to pump enough blood through the body.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/334f43844e4cdedc8b5328e7176dd66b.html)